Novel Vaccine Technologies and Platforms to Protect from Infectious Diseases

A special issue of Biologics (ISSN 2673-8449). This special issue belongs to the section "Vaccines".

Deadline for manuscript submissions: closed (1 May 2024) | Viewed by 3864

Special Issue Editors


E-Mail Website
Guest Editor
Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK, Canada
Interests: veterinary vaccines; adenovirus; porcine reproductive and respiratory virus
Special Issues, Collections and Topics in MDPI journals
1. Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada
2. Research and Development Department, Precision NanoSystems Inc., Vancouver, BC, Canada
Interests: antiviral vaccines; non-viral vaccine delivery and gene editing, expression, and silencing using non-viral vectors or lipid nanoparticles

Special Issue Information

Dear Colleagues,

Vaccines are crucial to maintaining public health, and they have demonstrated cost-effective benefits in protecting both humans and animals from infectious diseases. The majority of vaccines available today rely either on the attenuation or inactivation of infectious agents. However, both techniques have their limitations and potential associated problems. To overcome these problems, scientists have been working on the development of new vaccine technologies and platforms. These include subunit and virus-like particle (VLP) vaccines, synthetic peptide vaccines, polysaccharide, and polysaccharide-conjugated vaccines, bacterial and viral-vector-based vaccines, and DNA- as well as mRNA-based vaccines. Advances in novel vaccine technologies allowed us to quickly respond to the global epidimic caused by SARS-CoV-2; adenovirus-based and mRNA-based vaccines against SARS-CoV-2 were quickly developed and approved in many countries around the world. In the veterinary field, vaccines based on baculovirus or alphavirus vector platform technology can be quickly produced to target agents causing emerging diseases if traditional vaccines are ineffective. This Special Issue of Biologics will cover new research and developments in the area of new vaccine technologies and platforms.

Dr. Alexander Zakhartchouk
Dr. Sams Sadat
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biologics is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • virus-like particles
  • polysaccharide vaccine
  • next-generation vaccines
  • viral or bacterial vectored vaccine
  • replicon-based vaccine
  • DNA vaccine
  • mRNA vaccine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

16 pages, 753 KiB  
Review
Recent Advances in Arboviral Vaccines: Emerging Platforms and Promising Innovations
by Sujit Pujhari
Biologics 2024, 4(1), 1-16; https://doi.org/10.3390/biologics4010001 - 22 Dec 2023
Cited by 1 | Viewed by 3153
Abstract
Arboviruses are a group of viruses that are transmitted by arthropods, such as mosquitoes, and cause significant morbidity and mortality worldwide. Currently, there are only a few options, with restricted use, for effective vaccines against these viruses. However, recent advances in arboviral vaccine [...] Read more.
Arboviruses are a group of viruses that are transmitted by arthropods, such as mosquitoes, and cause significant morbidity and mortality worldwide. Currently, there are only a few options, with restricted use, for effective vaccines against these viruses. However, recent advances in arboviral vaccine development have shown promising innovations that have potential in preclinical and clinical studies. Insect-specific viruses have been explored as a novel vaccine platform that can induce cross-protective immunity against related arboviruses. Nanoparticle-based vaccines have also been developed to enhance the immunogenicity and stability of viral antigens. Additionally, vaccines against mosquito salivary proteins that can modulate the host immune response and interfere with arboviral transmission are being explored. Synonymous recoding, such as random codon shuffling, codon deoptimization, and codon-pair deoptimization, is being investigated as a strategy to attenuate the replication of arboviruses in vertebrate cells, reducing the risk of reverting to wild-type virulence. Finally, mRNA vaccines have been developed to rapidly generate and express viral antigens in the host cells, eliciting robust and durable immune responses. The challenges and opportunities for arboviral vaccine development are outlined, and future directions for research and innovation are discussed. Full article
Show Figures

Figure 1

Back to TopTop